Late-breaking data at 2022 aaaai annual meeting show dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis

Tarrytown, n.y. and paris, feb. 26, 2022 /prnewswire/ --  dupixent 300 mg weekly is the only biologic medicine to show positive, clinically meaningful phase 3 results in adults and adolescents with eosinophilic esophagitis eosinophilic esophagitis is a chronic, progressive type 2 inflammatory disease that damages the esophagus and prevents it from working properly   u.s. and global regulatory filings are planned in 2022 regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced positive detailed results from a second phase 3 trial that showed dupixent® (dupilumab) 300 mg weekly significantly improved the signs and symptoms of eosinophilic esophagitis (eoe) at 24 weeks compared to placebo in patients 12 years and older.
REGN Ratings Summary
REGN Quant Ranking